Fusidic acid is under clinical development by Aceragen and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Fusidic acid’s likelihood of approval (LoA) and phase transition for Burkholderia pseudomallei Infections (Melioidosis) took place on 10 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fusidic acid Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Fusidic acid overview
Fusidic acid is under development for the treatment of melioidosis, pulmonary exacerbations in patients with cystic fibrosis. TAKSTA is administered orally as fusidic acid tablet, an agent with activity against gram-positive bacteria. Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome.
It was under development for the treatment of acute skin and skin structure infections (sssi) caused by bacteria, refractory bone and joint infections (BJI) including prosthetic joint infections (including methicillin-resistant Staphylococcus aureus (MRSA) infections), chronic prosthetic joint infections and methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis.
Aceragen is a drug development company advancing a late-stage therapy for Farber disease. The company is headquartered in Raleigh, North Carolina, the US.
Quick View Fusidic acid LOA Data
|Highest Development Stage|